Basilea Pharmaceutica AG (BSLN) — Strategic Asset Allocation Index
Basilea Pharmaceutica AG (BSLN) has a Strategic Asset Allocation Index of 14.2% as of December 2025. Strategic assets (PP&E of CHF18.15 Million plus long-term investments of CHF-) total CHF18.15 Million, measured against net assets of CHF127.94 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check BSLN financial resilience to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Basilea Pharmaceutica AG Strategic Asset Allocation Index (2014–2025)
This chart shows how Basilea Pharmaceutica AG's Strategic Asset Allocation Index has evolved across 4 annual periods from 2014 to 2025. As of December 2025, the index stands at 14.2%, representing strategic assets of CHF18.15 Million against net assets of CHF127.94 Million CHF. See Basilea Pharmaceutica AG free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Basilea Pharmaceutica AG (2014–2025)
The table below presents the year-by-year Strategic Asset Allocation Index for Basilea Pharmaceutica AG from 2014 to 2025, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Basilea Pharmaceutica AG market capitalisation.
| Year | SAAI | Strategic Assets (CHF) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 14.2% | CHF18.15 Million | CHF18.15 Million | CHF- | CHF127.94 Million | ▼ -9.2 pp |
| 2024 | 23.4% | CHF18.98 Million | CHF18.98 Million | CHF- | CHF81.00 Million | ▼ -48.8 pp |
| 2015 | 72.2% | CHF10.72 Million | CHF10.72 Million | CHF- | CHF14.86 Million | ▲ +51.2 pp |
| 2014 | 21.0% | CHF12.16 Million | CHF12.16 Million | CHF- | CHF57.93 Million | — |